Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 68
Filtrar
1.
Pediatr Neonatol ; 64(6): 637-643, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37117074

RESUMEN

BACKGROUND: The survival rate of very low birth weight (VLBW) infants has recently improved. However, the occurrence of and factors associated with epilepsy in VLBW infants remain unknown. This study aimed to clarify the incidence, characteristics, and factors associated with epilepsy development in VLBW infants. METHODS: All VLBW infants admitted to our hospital between 2012 and 2017 were included in this study. VLBW infants with a follow-up period of <1 year were excluded. Chromosomal abnormalities, brain anomalies, severe intraventricular hemorrhage (IVH), cystic periventricular leukomalacia (PVL), and hypoxic ischemic encephalopathy (HIE) were considered to be risk factors. RESULTS: Epilepsy occurred in 21/526 (4.0%) VLBW infants. Chromosomal abnormalities, brain anomalies, severe IVH, cystic PVL, HIE, neonatal seizures, advanced maternal age, maternal diabetes mellitus, no administration of antenatal corticosteroids, and low Apgar scores at 1 and 5 min were associated with a risk of epilepsy. The median time to epilepsy onset was 8 months (range: 0-59 months), and the onset occurred within 2 years in 15/21 patients (71.4%) and within 4 years in 18/21 patients (85.7%). VLBW infants with risk factors developed epilepsy earlier and at a significantly higher rate than those without risk factors. Among infants who had risk factors and who developed epilepsy, 86.7% did so within 2 years of age, compared to 33.3% of those who developed epilepsy but did not have risk factors. CONCLUSION: These findings regarding factors associated with a risk of development of epilepsy and temporal feature of epilepsy may contribute to the development of monitoring and treatment protocols for epilepsy in VLBW infants.


Asunto(s)
Encefalopatías , Epilepsia , Enfermedades del Recién Nacido , Leucomalacia Periventricular , Recién Nacido , Lactante , Humanos , Femenino , Embarazo , Recién Nacido de muy Bajo Peso , Leucomalacia Periventricular/epidemiología , Factores de Riesgo , Hemorragia Cerebral/epidemiología , Epilepsia/epidemiología , Epilepsia/etiología , Aberraciones Cromosómicas , Peso al Nacer
2.
Brain Dev ; 44(7): 438-445, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-35393131

RESUMEN

OBJECTIVE: Children with attention deficit hyperactivity disorder (ADHD) often experience difficulties with emotional control and a consequent inability to perform tasks. To clarify the effects of emotional behavior on cognitive functions, we aimed to determine the association between emotional changes and executive functions in children with ADHD by measuring the pupil diameter changes associated with emotional changes. PARTICIPANTS AND METHODS: This study included 14 children with ADHD and 10 typically developing children (TDC) aged between 10 and 16 years. During the Wisconsin Card Sorting Test (WCST), which is related to context formation and task switching among executive functions, changes in pupil diameter and frontal oxygenated hemoglobin (oxy-Hb) using functional near-infrared spectroscopy (fNIRS) were recorded simultaneously. Pupil diameter changes during "cognitive shift" and "consecutive correction" were compared between both groups. RESULTS: During cognitive shift, the pupils of children with ADHD contracted, whereas those of the TDC were mydriatic. During consecutive correction, the pupils of children with ADHD were mydriatic, whereas those of the TDC tended to contract. These results correlated with WCST performance. Moreover, during cognitive shifts, changes in bilateral frontal blood flow were increased in TDC, but not in children with ADHD. CONCLUSION: The locus coeruleus-norepinephrine (LC-NE) system plays an important role in pupillary diameter response. These results suggest that the LC-NE system may be dysfunctional in children with ADHD, and the system's abnormality may lead to affective abnormalities in such patients, which results in poor performance on WCST (i.e., impaired executive functions).


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad , Función Ejecutiva , Adolescente , Niño , Emociones , Función Ejecutiva/fisiología , Humanos , Midriáticos , Pruebas Neuropsicológicas , Test de Clasificación de Tarjetas de Wisconsin
3.
JCI Insight ; 6(9)2021 05 10.
Artículo en Inglés | MEDLINE | ID: mdl-33830944

RESUMEN

Extensive activation of glial cells during a latent period has been well documented in various animal models of epilepsy. However, it remains unclear whether activated glial cells contribute to epileptogenesis, i.e., the chronically persistent process leading to epilepsy. Particularly, it is not clear whether interglial communication between different types of glial cells contributes to epileptogenesis, because past literature has mainly focused on one type of glial cell. Here, we show that temporally distinct activation profiles of microglia and astrocytes collaboratively contributed to epileptogenesis in a drug-induced status epilepticus model. We found that reactive microglia appeared first, followed by reactive astrocytes and increased susceptibility to seizures. Reactive astrocytes exhibited larger Ca2+ signals mediated by IP3R2, whereas deletion of this type of Ca2+ signaling reduced seizure susceptibility after status epilepticus. Immediate, but not late, pharmacological inhibition of microglial activation prevented subsequent reactive astrocytes, aberrant astrocyte Ca2+ signaling, and the enhanced seizure susceptibility. These findings indicate that the sequential activation of glial cells constituted a cause of epileptogenesis after status epilepticus. Thus, our findings suggest that the therapeutic target to prevent epilepsy after status epilepticus should be shifted from microglia (early phase) to astrocytes (late phase).


Asunto(s)
Astrocitos/metabolismo , Epilepsia/metabolismo , Receptores de Inositol 1,4,5-Trifosfato/metabolismo , Microglía/metabolismo , Estado Epiléptico/metabolismo , Animales , Astrocitos/efectos de los fármacos , Astrocitos/patología , Señalización del Calcio , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Susceptibilidad a Enfermedades , Epilepsia/inducido químicamente , Epilepsia/patología , Epilepsia/fisiopatología , Gliosis/metabolismo , Interleucina-1beta/metabolismo , Ratones , Microglía/efectos de los fármacos , Microglía/patología , Agonistas Muscarínicos/toxicidad , Compuestos Orgánicos/farmacología , Pilocarpina/toxicidad , Receptores de Factor Estimulante de Colonias de Granulocitos y Macrófagos/antagonistas & inhibidores , Bloqueadores de los Canales de Sodio/toxicidad , Estado Epiléptico/inducido químicamente , Estado Epiléptico/patología , Estado Epiléptico/fisiopatología , Tetrodotoxina/toxicidad , Factores de Tiempo , Factor de Necrosis Tumoral alfa/metabolismo
4.
Epilepsy Res ; 170: 106550, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-33450524

RESUMEN

AIM: The aim of this study was to assess the usefulness of perampanel (PER), and to identify the relationship between behavioral impairments and electroencephalogram (EEG) findings in epilepsy patients with autism spectrum disorder (ASD). METHODS: Participants were ASD patients with epilepsy recruited between June 1, 2016 and June 30, 2018. Inclusion criteria were: seizures refractory to two appropriate antiseizure medications (ASMs); presence of neuropsychological impairments; and ≥12 months of monitoring. PER was administered once daily, starting at a dose of 2 mg/day, increased to 12 mg/day. Seizure/EEG responders were identified as participants showing a >50 % reduction in seizure/interictal epileptiform discharge (IED) frequency (indicated as complete disappearance and response). Behavioral responders were identified as participants with a ≥50 % reduction in scores of the Japanese manuals for the Aberrant Behavior Checklist (ABC-J). RESULTS: Eleven (64.7 %) of 17 patients were considered to be both seizure and EEG responders. Five (45.5 %) of these 11 patients with seizure/EEG response were considered as behavioral responders. Mean ABC-J scores were significantly decreased at 12 months after PER administration (p = 0.0002). A correlation between decreased IED frequency and ABC-J score was evident in frontal IEDs, but not in non-frontal IEDs. Participants presenting with frontal IEDs showed a significantly higher correlation between seizures/EEG and behavioral improvements (p = 0.023). Moreover, 2 of 6 patients without seizure/EEG improvement were considered as behavioral responders. No patients discontinued PER. CONCLUSIONS: The results from this study suggest the utility of PER treatment in reducing clinical seizures and IEDs for ASD patients with intractable epilepsy, at least in some patients. Moreover, the present results also indicate the usefulness of PER in improving neuropsychiatric impairments, including behavioral disturbances in ASD related to improvement of clinical seizures/frontal IEDs, but also unrelated to seizure/EEG improvement in at least some ASD patients.


Asunto(s)
Trastorno del Espectro Autista , Epilepsia , Trastorno del Espectro Autista/complicaciones , Trastorno del Espectro Autista/tratamiento farmacológico , Electroencefalografía , Epilepsia/tratamiento farmacológico , Humanos , Nitrilos , Piridonas , Convulsiones/tratamiento farmacológico
5.
Pediatr Neurol ; 113: 43-45, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-33011640

RESUMEN

BACKGROUND: Clinically mild encephalopathy with a reversible splenial lesion (MERS) is the second commonest cause of encephalopathy. Several pathogens have been detected in patients with MERS type 2, such as influenza A and B, but little is known about the proportion of cases of MERS type 2 with this pathogenesis. Human herpesvirus 6 (HHV6) is the second commonest pathogen causing acute encephalopathy. However, HHV6 has not been previously reported in patients with MERS type 2. PATIENT DESCRIPTION: In this report, we describe a five-year-old boy with MERS type 2 caused by HHV6 infection. The present case was diagnosed with MERS type 2 caused by HHV6 infection based on the characteristic clinical course, the results of the virus testing, and imaging findings. DISCUSSION: This is the first description of MERS type 2 caused by HHV6 infection. Although there is a report of MERS type 1 caused by HHV6 infection, there are no detailed reports in the literature about MERS type 2 associated with HHV6 infection. Thus the clinical findings associated with MERS type 2 caused by HHV6 infection are poorly understood. This report indicates that HHV6 can cause MERS type 2.


Asunto(s)
Encefalopatías/patología , Encefalopatías/virología , Cuerpo Calloso/patología , Herpesvirus Humano 6 , Infecciones por Roseolovirus/complicaciones , Infecciones por Roseolovirus/diagnóstico , Encefalopatías/diagnóstico por imagen , Preescolar , Cuerpo Calloso/diagnóstico por imagen , Humanos , Imagen por Resonancia Magnética , Masculino
6.
Seizure ; 80: 131-137, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32570169

RESUMEN

PURPOSE: The purpose of this study was to determine the efficacy of perampanel (PER) on secondary bilateral synchrony (SBS) and behavioral problems in adolescents with epilepsy who showed insufficient response to levetiracetam (LEV). METHODS: The primary criterion for patient selection was the presence of SBS. The criteria such as age between 12 and 18 years, seizures refractory to antiseizure medications including LEV, at least four seizures a month, neuropsychological impairments, and at least 12 months of follow-up also had to be fulfilled. Patients were given PER at an initial dose of 2 mg/day, followed by increments of +2 mg/day every 2 weeks. Concomitant medications remained unchanged during evaluation period. Responders for electroencephalogram (EEG) and seizures were identified as showing a ≥50 % reduction from the baseline SBS on EEG and seizure frequency, respectively. Neuropsychological impairments as per the Japanese manuals for the Aberrant Behavior Checklist (ABC-J) were evaluated before and after PER administration. RESULTS: Eight of 14 patients were considered responders for seizures. Among these 8 responders, 6 patients were considered responders for EEG and behavioral problems. Mean ABC-J scores in both EEG non-responders and responders were decreased significantly at 12 months (p < 0.05 and p < 0.05, respectively). ABC-J scores were significantly lower in EEG responders than in EEG non-responders at 12 months (p < 0.01). Moreover, among patients with decreased ABC-J scores, the degree of decrease was larger in EEG responders than in EEG non-responders (p < 0.01). CONCLUSIONS: PER may be useful in reducing SBS on EEG, seizure frequency, and behavioral problems.


Asunto(s)
Epilepsia , Piracetam , Problema de Conducta , Adolescente , Anticonvulsivantes/uso terapéutico , Epilepsia/tratamiento farmacológico , Humanos , Lactante , Levetiracetam/uso terapéutico , Nitrilos , Piracetam/uso terapéutico , Piridonas , Resultado del Tratamiento
7.
J Atten Disord ; 24(14): 2012-2020, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-29154696

RESUMEN

Objective: To establish valid, objective biomarkers for ADHD using machine learning. Method: Machine learning was used to predict disorder severity from new brain function data, using a support vector machine (SVM). A multicenter approach was used to collect data for machine learning training, including behavioral and physiological indicators, age, and reverse Stroop task (RST) data from 108 children with ADHD and 108 typically developing (TD) children. Near-infrared spectroscopy (NIRS) was used to quantify change in prefrontal cortex oxygenated hemoglobin during RST. Verification data were from 62 children with ADHD and 37 TD children from six facilities in Japan. Results: The SVM general performance results showed sensitivity of 88.71%, specificity of 83.78%, and an overall discrimination rate of 86.25%. Conclusion: A SVM using an objective index from RST may be useful as an auxiliary biomarker for diagnosis for children with ADHD.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad , Trastorno por Déficit de Atención con Hiperactividad/diagnóstico , Niño , Humanos , Japón , Aprendizaje Automático , Corteza Prefrontal , Espectroscopía Infrarroja Corta
8.
Brain Dev ; 41(7): 577-586, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-30952459

RESUMEN

BACKGROUND: The neural correlates of executive function disorders are thought to be predominantly localized within the prefrontal cortex (PFC). However, no study to date has investigated changes in this system across different age groups in children with attention deficit hyperactivity disorder (ADHD). Thus, this study aimed to explore changes in PFC function in children with ADHD. METHODS: Study participants included typically developing (TD) children (n = 140) and children with ADHD (n = 67) of primary school age. Behavioral executive functions and their neural basis were evaluated between the TD children and children with ADHD and also across different age periods (younger and older children). To examine executive function, inhibitory control was assessed using the reverse Stroop task, and PFC near-infrared spectroscopic measurements were used to investigate the neural mechanisms involved. RESULTS: Both ADHD symptoms and the ability to inhibit color interference improved with age. Compared to TD children, children with ADHD demonstrated decreased activation of the right and middle PFC across all age groups. Interestingly, the left PFC appeared to play a compensatory role. CONCLUSION: Children with ADHD exhibited changes in PFC function that varied with age. Longitudinal studies are required to assess the potential of using PFC function as an early biomarker of ADHD.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad/fisiopatología , Lóbulo Frontal/fisiopatología , Factores de Edad , Trastorno por Déficit de Atención con Hiperactividad/diagnóstico por imagen , Trastorno por Déficit de Atención con Hiperactividad/metabolismo , Mapeo Encefálico/métodos , Niño , Función Ejecutiva/fisiología , Femenino , Lóbulo Frontal/diagnóstico por imagen , Humanos , Procesamiento de Imagen Asistido por Computador/métodos , Imagen por Resonancia Magnética/métodos , Masculino , Corteza Prefrontal/diagnóstico por imagen , Corteza Prefrontal/fisiopatología , Espectroscopía Infrarroja Corta/métodos
9.
Eur J Paediatr Neurol ; 23(1): 197-203, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30424990

RESUMEN

PURPOSE: The purpose was to evaluate the efficacy of treatment and the occurrence of aggression-related adverse events among children receiving perampanel (PER) with concomitant levetiracetam (LEV). METHODS: Patients were selected according to the following criteria: 1) between 12 and 18 years old; 2) seizures refractory to at least 2 first-line drugs; 3) at least 4 seizures a month before PER administration; and 4) at least 12 months of follow-up. Patients were subdivided into groups with and without LEV as concomitant treatment. PER was administered at a dose of 2 mg/day, increasing by 2 mg/day every 2 weeks up to 12 mg/day if seizures appeared. In comparison with the baseline seizure frequency, response to PER treatment was classified as follows: complete cessation (100% seizure control); response (≥50% reduction in seizures); and exacerbation (≥50% increase in seizures). Responders were identified as patients showing complete cessation or response. RESULTS: The study group comprised 39 outpatients with a mean age of 13.7 years at enrollment. Responder status was seen in 13 of the 19 patients with LEV and 4 of the 20 patients without LEV. PER appeared significantly more effective in patients with LEV than in those without LEV (p = 0.0076). Seizure-free status was significantly more frequent among patients with LEV (47.4%) than among those without LEV (15.0% (p = 0.0407)). Aggression was present in 2 patients without LEV, but none with LEV. CONCLUSION: The present study suggests the utility of PER with concomitant LEV for children with drug-resistant epilepsy.


Asunto(s)
Anticonvulsivantes/administración & dosificación , Epilepsia Refractaria/tratamiento farmacológico , Levetiracetam/administración & dosificación , Piridonas/administración & dosificación , Adolescente , Agresión/efectos de los fármacos , Anticonvulsivantes/efectos adversos , Niño , Preescolar , Quimioterapia Combinada , Femenino , Humanos , Levetiracetam/efectos adversos , Masculino , Trastornos Mentales/inducido químicamente , Trastornos Mentales/epidemiología , Nitrilos , Piridonas/efectos adversos , Resultado del Tratamiento
10.
Seizure ; 62: 79-83, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30308427

RESUMEN

PURPOSE: The main purpose of this study was to compare the efficacy of levetiracetam (LEV) with the older antiepileptic drugs (AEDs) for preventing atypical evolution in children with Rolandic epilepsy (RE). Accordingly, the present study compared the efficacy of older AEDs (carbamazepine (CBZ) and valproate sodium (VPA)) with LEV in reducing rolandic discharges (RDs) on interictal electroencephalogram (EEG) in children with RE. METHODS: Patients in this heterogenous study were subdivided into CBZ, VPA and LEV groups in accordance with the initial monotherapy. The CBZ and VPA groups were studied retrospectively, but the LEV group was studied prospectively. Appearances of discharges were counted and these rates were computed. In comparison with the baseline RD frequency, EEG response to AED treatment was classified such as complete disappearance and response (≥50% reduction in RD frequency). The time taken to attain complete disappearance or response in EEG responders was assessed for each AED treatment group. RESULTS: Responders comprised 10 (11.2%) of the 89 patients treated with CBZ, 41 (56.2%) of the 73 patients with VPA, and 25 (71.4%) of the 35 patients with LEV. Mean interval to achievement of EEG response in the CBZ, VPA, and LEV groups were 36.3, 23.1, and 14.7 months, respectively. EEG response was achieved significantly more rapidly with LEV than with CBZ (p < 0.001) or VPA (p < 0.005). Seizure control was not significantly different in all 3 investigated drugs. CONCLUSIONS: LEV seems to be superior to CBZ and VPA in its ability to suppress RDs in children with RE.


Asunto(s)
Anticonvulsivantes/uso terapéutico , Ondas Encefálicas/efectos de los fármacos , Epilepsia Rolándica/tratamiento farmacológico , Epilepsia Rolándica/fisiopatología , Carbamazepina/uso terapéutico , Niño , Preescolar , Electroencefalografía , Femenino , Estudios de Seguimiento , Humanos , Estimación de Kaplan-Meier , Levetiracetam/uso terapéutico , Masculino , Ácido Valproico/uso terapéutico
11.
Epilepsia ; 59(10): 1867-1880, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-30178479

RESUMEN

Attention-deficit/hyperactivity disorder (ADHD) is a common and challenging comorbidity affecting many children with epilepsy. A working group under the International League Against Epilepsy (ILAE) Pediatric Commission identified key questions on the identification and management of ADHD in children with epilepsy. Systematic reviews of the evidence to support approaches to these questions were collated and graded using criteria from the American Academy of Neurology Practice Parameter. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) requirements were followed, with PROSPERO registration (CRD42018094617). No increased risk of ADHD in boys with epilepsy compared to girls with epilepsy was found (Level A). Valproate use in pregnancy is associated with inattentiveness and hyperactivity in offspring (1 class I study), and children with intellectual and developmental disabilities are at increased risk of ADHD (Level A). Impact of early seizure onset on development of ADHD was unclear (Level U), but more evident with poor seizure control (Level B). ADHD screening should be performed from 6 years of age, or at diagnosis, and repeated annually (Level U) and reevaluated after change of antiepileptic drug (AED) (Level U). Diagnosis should involve health practitioners with expert training in ADHD (Level U). Use of the Strength and Difficulties Questionnaire screening tool is supported (Level B). Formal cognitive testing is strongly recommended in children with epilepsy who are struggling at school (Level U). Behavioral problems are more likely with polytherapy than monotherapy (Level C). Valproate can exacerbate attentional issues in children with childhood absence epilepsy (Level A). Methylphenidate is tolerated and effective in children with epilepsy (Level B). Limited evidence supports that atomoxetine is tolerated (Level C). Multidisciplinary involvement in transition and adult ADHD clinics is essential (Level U). In conclusion, although recommendations could be proposed for some of the study questions, this systematic review highlighted the need for more comprehensive and targeted large-population prospective studies.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad , Manejo de la Enfermedad , Epilepsia , Anticonvulsivantes/uso terapéutico , Trastorno por Déficit de Atención con Hiperactividad/complicaciones , Trastorno por Déficit de Atención con Hiperactividad/diagnóstico , Trastorno por Déficit de Atención con Hiperactividad/epidemiología , Trastorno por Déficit de Atención con Hiperactividad/terapia , Estimulantes del Sistema Nervioso Central/uso terapéutico , Epilepsia/complicaciones , Epilepsia/diagnóstico , Epilepsia/epidemiología , Epilepsia/terapia , Humanos
12.
J Paediatr Child Health ; 54(12): 1336-1340, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-29806871

RESUMEN

AIM: The purpose of this study was to examine the association between seizure-related features and fatigue levels in children with epilepsy. METHODS: All children were classified into three subgroups based on the state of their seizure control: well-controlled epilepsy (WCE; seizure-free), intermediate-controlled epilepsy (ICE; seizure frequency < 1×/month) and uncontrolled epilepsy (UCE; seizure frequency > 1×/month). Participants were asked to rate on a 7-point scale, from 1 (strongly disagree) to 7 (strongly agree), how often they felt the ways described by nine items on the Fatigue Severity Scale (FSS). A higher score is suggestive of greater fatigue. RESULTS: The study participants comprised 58 children with epilepsy and 15 children without seizures, who served as the healthy (non-epilepsy) group. The mean FSS scores of the children with epilepsy were significantly higher than those of the healthy (non-epilepsy) group (4.40 vs. 1.55, respectively; P < 0.0001). Multiple linear regression analysis showed that seizure frequency was the only characteristic significantly associated with fatigue (P < 0.0001). In the three epilepsy subgroups, the mean FSS scores for the WCE, intermediate-controlled epilepsy and UCE groups were 2.30, 3.97 and 6.28, respectively. A higher seizure frequency was associated with more severe fatigue. In particular, children in the UCE group had significantly more severe fatigue than those in the WCE group (P < 0.0001). CONCLUSIONS: The results suggest that seizure frequency is also associated with fatigue in children with epilepsy. Improved control of seizures may help reduce fatigue levels and improve the quality of life of children with epilepsy.


Asunto(s)
Epilepsia/fisiopatología , Fatiga/etiología , Convulsiones/complicaciones , Adolescente , Niño , Fatiga/fisiopatología , Femenino , Humanos , Japón , Masculino , Calidad de Vida , Encuestas y Cuestionarios
13.
Neuropediatrics ; 49(2): 135-141, 2018 04.
Artículo en Inglés | MEDLINE | ID: mdl-29253909

RESUMEN

This article compares the efficacy and tolerability of carbamazepine (CBZ) and levetiracetam (LEV) when used as initial monotherapy in children with nonlesional focal epilepsy. Patients with nonlesional focal epilepsy were subdivided into two groups according to the initial monotherapy: a LEV group administered LEV at an initial dose of 5 mg/kg/day and a CBZ group. Seizure response, adverse events, medication dose, reasons for discontinuing medication, adherence, and random serum levels were recorded. The overall percentage of patients who failed initial treatment and reasons for each treatment failure were determined. Data were analyzed from 183 children who received CBZ monotherapy and 46 children who received LEV monotherapy for ≥12 months. Overall, 126 patients (68.9%) became seizure-free with CBZ, compared with 37 patients (80.4%) with LEV. Moreover, four patients in CBZ and four patients in LEV groups showed a >50% reduction in seizure frequency. The efficacy rate was significantly higher and the adverse event rate was significantly lower in the LEV group than in the CBZ group (p = 0.0129 and p = 0.0039, respectively). LEV may offer superior efficacy and a lower risk of adverse effects compared with CBZ. LEV as initial monotherapy may represent a valuable treatment option for children with nonlesional focal childhood epilepsy.


Asunto(s)
Anticonvulsivantes/uso terapéutico , Epilepsias Parciales/tratamiento farmacológico , Epilepsia Rolándica/tratamiento farmacológico , Levetiracetam/uso terapéutico , Niño , Preescolar , Electroencefalografía , Femenino , Estudios de Seguimiento , Humanos , Lactante , Masculino , Estudios Retrospectivos , Resultado del Tratamiento
14.
Brain Dev ; 39(7): 573-582, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28377150

RESUMEN

OBJECTIVE: Autonomic nervous system activity is recognized as a major component of emotional responses. Future reward/punishment expectations depend upon the process of decision making in the frontal lobe, which is considered to play an important role in executive function. The aim of this study was to investigate the relationship between autonomic responses and decision making during reinforcement tasks using sympathetic skin responses (SSR). METHODS: Nine adult and 9 juvenile (mean age, 10.2years) volunteers were enrolled in this study. SSRs were measured during the Markov decision task (MDT), which is a reinforcement task. In this task, subjects must endure a small immediate loss to ultimately get a large reward. The subjects had to undergo three sets of tests and their scores in these tests were assessed and evaluated. RESULTS: All adults showed gradually increasing scores for the MDT from the first to third set. As the trial progressed from the first to second set in adults, SSR appearance ratios remarkably increased for both punishment and reward expectations. In comparison with adults, children showed decreasing scores from the first to second set. There were no significant inter-target differences in the SSR appearance ratio in the first and second set in children. In the third set, the SSR appearance ratio for reward expectations was higher than that in the neutral condition. CONCLUSIONS: In reinforcement tasks, such as MDT, autonomic responses play an important role in decision making. We assume that SSRs are elicited during efficient decision making tasks associated with future reward/punishment expectations, which demonstrates the importance of autonomic function. In contrast, in children around the age of 10years, the autonomic system does not react as an organized response specific to reward/punishment expectations. This suggests the immaturity of the future reward/punishment expectations process in children.


Asunto(s)
Anticipación Psicológica/fisiología , Sistema Nervioso Autónomo/crecimiento & desarrollo , Sistema Nervioso Autónomo/fisiología , Toma de Decisiones/fisiología , Castigo , Recompensa , Adulto , Niño , Emociones/fisiología , Femenino , Humanos , Masculino , Pruebas Neuropsicológicas , Fenómenos Fisiológicos de la Piel
15.
Brain Dev ; 39(5): 395-402, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28094161

RESUMEN

OBJECTIVE: Attention-deficit/hyperactivity disorder (AD/HD) is a common developmental disorder. Many reports have suggested that symptoms of AD/HD are related to frontal lobe dysfunctions, particularly disinhibition. However, measuring neurological findings with biomarkers during frontal functional tasks has sometimes been difficult in children with AD/HD. This study aimed to investigate frontal inhibitory function objectively in children with AD/HD during "rock, paper, scissors" (RPS) tasks, as a familiar game for Japanese children, using near-infrared spectroscopy (NIRS). SUBJECTS AND METHODS: Eighteen children with AD/HD were compared with 27 typically developing children (TDC). Children from each group were divided into two age groups: younger, 6-10years; and older, 11-16years. Changes in oxygenated hemoglobin [oxy-Hb] were measured in the prefrontal region using NIRS during a 'to lose' RPS task, in which subjects were asked to present the RPS signal that would lose in response to one of the three signals displayed randomly on a computer screen every 2.0s. RESULTS: The rate of correct performance with both TDC and AD/HD increased with age. Only in the older group, the rate of correct performance was significantly higher with TDC than with AD/HD. However, children with AD/HD in both age groups showed significantly lower [oxy-Hb] activity in the prefrontal region during the 'to lose' RPS task, particularly in the dorsolateral area. CONCLUSIONS: Our results suggest that prefrontal region activation during the 'to lose' RPS task could offer a biomarker for diagnosing AD/HD, and may help in the early treatment of AD/HD.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad/metabolismo , Conducta de Elección/fisiología , Lóbulo Frontal/diagnóstico por imagen , Oxihemoglobinas/metabolismo , Desempeño Psicomotor/fisiología , Espectroscopía Infrarroja Corta , Adolescente , Factores de Edad , Trastorno por Déficit de Atención con Hiperactividad/diagnóstico por imagen , Niño , Femenino , Humanos , Masculino , Pruebas Neuropsicológicas , Estadística como Asunto
16.
No To Hattatsu ; 49(2): 113-9, 2017 03.
Artículo en Japonés | MEDLINE | ID: mdl-30113151

RESUMEN

Objective: Bone fractures in patients with severe motor and intellectual disabilities (SMIDs) have become an important problem to be solved. These fractures may result from disuse osteoporosis. Bisphosphonate administration is generally the most established treatment for patients with osteoporosis. However, traditional oral bisphosphonate use is associated with esophagitis as a side effect and may increase the risk of reflux esophagitis for bedridden patients. Intravenous alendronate, one of the bisphosphonates, was released in 2012 in Japan. Though it is appropriate for patients with SMIDs, there are no reports about the effects of intravenous alendronate on osteoporosis in SMID patients. Therefore, the efficacy of intravenous alendronate for osteoporosis was investigated in SMID patients. Methods: The subjects were 62 SMID patients with osteoporosis (20 to 60 years old) in our hospital. They were divided two groups, bisphosphonate treatment group (32 patients) and age-matched controls (30 patients). Patients in bisphosphonate treatment groups were given 900µg intravenous alendronate once a month. All patients were also administered oral vitamin D3. Serial bone density, bone metabolism markers, and existence of fractures were compared in both groups before and after treatment (6 months, 1 years, and 2 years). Results: In bisphosphonate treatment group, the change rate of bone density was significantly increased and bone metabolism markers were improved at 6 months and 1 year after starting treatment. After a year, 16 patients in treatment group changed into other treatments, and 12 controls started bisphosphonate treatment. In remaining treatment group (16 patients), the change rate of bone density and bone metabolism markers were improved significantly at 2 years after starting treatment. A patient in control group had a bone fracture, but no patients in bisphosphonate treatment groups had fractures or severe adverse effects. Conclusion: Intravenous alendronate is an effective treatment for osteoporosis in SMID patients.


Asunto(s)
Alendronato/uso terapéutico , Conservadores de la Densidad Ósea/uso terapéutico , Discapacidad Intelectual/complicaciones , Trastornos del Movimiento/complicaciones , Osteoporosis/tratamiento farmacológico , Adulto , Alendronato/administración & dosificación , Conservadores de la Densidad Ósea/administración & dosificación , Femenino , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Osteoporosis/complicaciones , Adulto Joven
17.
Brain Dev ; 39(3): 187-195, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-27839927

RESUMEN

OBJECTIVE: The autonomic nervous system has a deep relationship with the cognitive network when performing cognitive tasks. We hypothesize that autonomic emotional responses can affect cognitive function, especially executive function. The aim of this study was to clarify the involvement of the autonomic system during an executive functional task via developmental changes assessed using pupillometry. SUBJECTS AND METHODS: Subjects were 16 healthy children and 9 healthy adults. Children were divided into 3 groups (Group A, 7-9years; Group B, 10-14years; Group C, 15-17years). Pupil diameter was recorded using an eye mark recorder during cognitive shift (CS) during the Wisconsin card sorting test (WCST). The rate of pupil variations was integrated and compared within each group, focusing on performance during CS. RESULTS: Categories achieved (CA) in the behavioral results of WCST increased with age, with significant differences between Group A and other groups. The change of pupillary diameter was increased with CS and decreased at the correct answers after CS in adults. Changes of pupillary diameter with CS showed a linear increase with age, and the pattern of the pupillary response at the age of 10-14years was comparable to adults. The integrated rate of pupil diameter with CS increased with age, and there was a significant difference between Group A and adults. In addition, the degree of mydriasis correlated with the number of CA. CONCLUSION: These findings suggest that autonomic emotional response play an important role as a part of the process for executive function.


Asunto(s)
Sistema Nervioso Autónomo/fisiología , Cognición/fisiología , Emociones/fisiología , Función Ejecutiva/fisiología , Pruebas Neuropsicológicas , Adolescente , Adulto , Femenino , Humanos , Masculino , Análisis y Desempeño de Tareas , Adulto Joven
18.
Epilepsy Behav ; 63: 42-45, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27565436

RESUMEN

AIMS: To develop and implement interventions to improve the quality of life (QOL) in children with epilepsy, it is important for clinicians and researchers to understand the effects of the children's parents' perception of stigma. The purpose of this study was to identify a relationship between patient clinical characteristics and perception of stigma in the parents of children with epilepsy. METHODS: Parents of children with epilepsy were recruited from our university hospital between April 1, 2005 and March 31, 2012. Items for the Parent Stigma Scale were developed from the literature and open-ended interviews with parents of children with epilepsy about their concerns and fears, including those related to stigma. Parents were asked to respond to five items, each on a 5-point scale from 1 (strongly disagree) to 5 (strongly agree). Assessments were performed for each clinical characteristic, such as child's sex, age at seizure onset, family history of epilepsy, seizure frequency, presence of status epilepticus (SE), presence of treatment-related adverse events, and the scores of each scale. RESULTS: A total of 52 parents of children with epilepsy and 10 parents of healthy children were enrolled in the study. Parents of children with epilepsy showed significantly higher scores on the questionnaire than parents of healthy children. In multiple regression analysis, greater perceptions of stigma were associated with a seizure frequency of more than one per month (p=0.0036, B=1.104, ß=0.402). In contrast, the presence of prior febrile seizures (p=0.0034, B=-1.297, ß=-0.308) and family history of epilepsy (p=0.0066, B=-1.613, ß=-0.277) were associated with lower perceptions of stigma. Greater parental perceptions of stigma were seen with the presence of monthly seizures. CONCLUSIONS: Parents of children with epilepsy are at risk of significant perceptions of stigma. Seizure severity, indicated by the presence of monthly seizures, was associated with greater perceptions of stigma in parents. In addition, the presence of prior febrile seizures and family history of epilepsy were associated with fewer perceptions of stigma. The findings of this study emphasize the importance of acknowledging and addressing parental perceptions of stigma.


Asunto(s)
Epilepsia/psicología , Padres/psicología , Calidad de Vida/psicología , Convulsiones/psicología , Estigma Social , Actitud Frente a la Salud , Niño , Preescolar , Epilepsia/diagnóstico , Femenino , Humanos , Masculino , Convulsiones/diagnóstico
19.
Neuropediatrics ; 47(4): 233-7, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27227999

RESUMEN

The aim of this study was to determine the efficacy of sunlight exposure for increasing bone mineral density (BMD) in children with severe disability. The subjects were five children with severe disability, aged 6 to 8 years. BMD was measured at baseline and after 3, 6, 9, and 12 months of starting sunlight exposure. All caregivers of patients were instructed to create opportunities to stay outdoors. Daily sunlight exposure time was defined as hours of staying outdoors. Mean hours of sunbathing per day were calculated at baseline and after 3, 6, 9, and 12 months of starting sunlight exposure. Sunlight exposure tended to be longer after starting than before starting in all patients, but the difference was not significant (p = 0.052). Along with the increase in sunlight exposure, BMD increased significantly after the start of sunlight exposure in all patients (p < 0.01). The serum values of total alkaline phosphatase and intact parathyroid hormone were significantly decreased and that of 25-hydroxyvitamin D was significantly increased 12 months after starting sunlight exposure. No patients had bone fractures after the start of sunlight exposure. These results suggest that sunlight exposure increased BMD, and that this may reduce the risk of bone fracture in children with disability.


Asunto(s)
Fosfatasa Alcalina/sangre , Densidad Ósea , Niños con Discapacidad , Hipoxia-Isquemia Encefálica , Hormona Paratiroidea/sangre , Luz Solar , Vitamina D/análogos & derivados , Absorciometría de Fotón , Niño , Femenino , Humanos , Masculino , Índice de Severidad de la Enfermedad , Vitamina D/sangre
20.
No To Hattatsu ; 48(4): 282-6, 2016 Jul.
Artículo en Japonés | MEDLINE | ID: mdl-30011143

RESUMEN

We report the case of a 5-year-old boy with acute encephalopathy presenting with transient executive dysfunction such as functional disability in various new tasks and hypoperfusion of the right frontal and temporal lobes on single photon emission tomography (SPECT). He presented with a 2-day history of disturbed consciousness, and electroencephalography in an awaked state showed diffuse high-voltage slow waves. Although MRI did not show any abnormality 3 days after initial onset of illness, SPECT showed hypoperfusion of the right frontal and temporal lobes at the same time. At 20 days after onset, the Kaufman assessment battery for children (K-ABC) test showed that sequential processing scale scores were significantly lower than simultaneous processing scale and achievement scale scores. He showed transient executive dysfunction such as functional disability in various new tasks at the same time. Abnormal brain perfusion on SPECT was improved at 8 months after onset and the sequential processing scale of K-ABC was likewise improved at 12 months after onset. These findings suggest that SPECT is helpful for diagnosing pathophysiological mechanisms with acute encephalopathy, and the combination of neuropsychological examination and SPECT study is useful for evaluating higher brain dysfunctions such as executive dysfunction.


Asunto(s)
Encefalopatías/fisiopatología , Lóbulo Frontal/irrigación sanguínea , Lóbulo Frontal/fisiopatología , Lóbulo Temporal/irrigación sanguínea , Lóbulo Temporal/fisiopatología , Circulación Cerebrovascular , Preescolar , Electroencefalografía , Humanos , Masculino , Tomografía Computarizada de Emisión de Fotón Único
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...